Compare IDEXX Laboratories, Inc. (IDXX) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs US Bancorp — how do they compare? IDEXX Laboratories, Inc. trades at $572.98 (market cap $46.22B), while US Bancorp trades at $64.58 (market cap $100.17B). The key difference: US Bancorp is far larger — about 2.2× IDEXX Laboratories, Inc.'s market cap, and US Bancorp pays a 3.24% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | USB | |
|---|---|---|
Market Cap | $46.22B | $100.17B |
Sector | Health | Financials |
52-Week High | $766.68 | $64.47 |
52-Week Low | $526.44 | $45.28 |
Enterprise Value | $47.12B | — |
Dividend Yield | — | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
U.S. Bancorp (USB) trades at $64.19, up 0.39% today, with a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $1.35 surpassing the $1.28 expectation. Revenue and net income have shown steady growth, with 2025 revenue at $28.54 billion and net income at $7.57 billion. Analyst sentiment is positive, with a consensus price target of $70.27, indicating potential upside.
The outlook for USB is favorable, supported by robust earnings growth, a solid dividend, and positive analyst ratings. Key risks include exposure to interest rate fluctuations and macroeconomic volatility, as highlighted by recent news on potential Fed rate hikes. Institutional investors have been increasing stakes, reinforcing confidence. The stock presents a compelling opportunity for value-oriented investors seeking steady returns amid a stable banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
